Tony Hickson is the Chief Business Officer for Cancer Research UK. Prior to joining CRUK, Tony was the Managing Director of Imperial Innovations Ltd, executive director on the board of Touchstone Innovations plc. Prior to joining Imperial Innovations, he had 15 years of commercial and business development experience in bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited.  

Tony has acted as a board director or observer for a number of start-up companies, including Polytherics (now Abzena), Catapult Therapy TCR, Zihipp and Precision Robotics, and was instrumental in the creation and development of companies such as Thiakis (sold to Wyeth/Pfizer in 2008), Respivert (sold to J&J in 2010), Circassia (listed on LSE in 2014), EMcision (sold to Boston Scientific in 2018) and Cell Medica (in advanced clinical studies).

Tony is a member of the BBSRC industry advisory panel and a Board Director of PraxisAuril. He has a diploma in company direction from the Institute of Directors and is a Certified Licensing Professional.